急性髓系白血病(acute myeloid leukemia,AML)是最常见的血液系统恶性肿瘤,蒽环类药物与阿糖胞苷的“3+7”方案仍是标准诱导方案。随着蒽环类新药的出现及剂量的优化,60%~85%的患者经标准“3+7”方案诱导治疗获得完全缓解,但老年患者并不能从标准方案中获益。因此,探索老年患者的化疗策略仍是目前亟需解决的问题。我们采用地西他滨联合半量CAG方案诱导治疗老年 Acute myeloid leukemia (AML) is the most common hematological malignancy and the “3 + 7” regimen of anthracyclines and cytarabine remains the standard induction regimen. With the advent of anthracyclines and dose optimization, 60% to 85% of patients achieved complete remission after induction with standard “3 + 7” regimen, but elderly patients do not benefit from the standard regimen. Therefore, to explore the strategy of chemotherapy in elderly patients remains an urgent problem to be solved. We use gemcitabine combined with half-dose CAG induction therapy for the elderly